Moderna (MRNA) Earnings Analysis

Moderna (MRNA) next reports earnings on 2026-07-31, consensus EPS -2 USD. Last quarter (2026-05-01) it beat with EPS -3.4 USD vs -4.45 USD est (+23.6%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E -7.13.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MRNA next report earnings?

Next earnings date2026-07-31
Consensus EPS estimate-2 USD
Revenue estimate0.10B

MRNA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-01-3.4 USD-4.45 USD+23.6%Beat
2026-02-13-2.11 USD-2.54 USD+16.9%Beat
2025-08-01-2.13 USD-2.99 USD+28.8%Beat
2025-05-01-2.52 USD-2.92 USD+13.7%Beat
2025-02-14-2.5 USD-2.68 USD+6.7%Beat
2024-08-01-3.33 USD-3.35 USD+0.6%Beat

Beat rate: 6/6 (100%) over reported quarters with consensus data.

MRNA valuation and analyst view

Trailing P/E-7.13
Trailing EPS-8.08608 USD
Price / book3.10
Dividend yield0.00%
Market cap23.26B
Analyst consensusHold (7 buy / 16 hold / 4 sell)
Avg price target46.44 USD

Related research pages

Frequently asked questions

When is Moderna (MRNA)'s next earnings date?

Moderna is next scheduled to report on 2026-07-31, with a consensus EPS estimate of -2 USD and revenue estimate of 0.10B.

Did MRNA beat earnings last quarter?

In its 2026-05-01 report, MRNA posted EPS of -3.4 USD versus a -4.45 USD estimate — a beat of 23.6%.

What is MRNA's earnings track record?

Over the last 6 reported quarters with consensus data, MRNA beat estimates 6 times (100%).

What is MRNA's current P/E ratio and EPS?

MRNA trades at a trailing P/E of -7.13 on trailing EPS of -8.086075949367089 USD.

What do analysts rate MRNA?

Analyst consensus is "Hold" across 27 ratings (0 strong buy, 7 buy, 16 hold, 4 sell, 0 strong sell). Average 12-month price target: 46.44 USD.